Based on the USANA Health Sciences Inc stock forecast from 1 analysts, the average analyst target price for USANA Health Sciences Inc is USD 37.00 over the next 12 months. USANA Health Sciences Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of USANA Health Sciences Inc is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, USANA Health Sciences Inc’s stock price was USD 24.74. USANA Health Sciences Inc’s stock price has changed by -2.90% over the past week, -25.28% over the past month and -45.39% over the last year.
No recent analyst target price found for USANA Health Sciences Inc
No recent average analyst rating found for USANA Health Sciences Inc
Company Overview USANA Health Sciences Inc
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah. Read Less
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mi...Read More
Frequently Asked Questions About USANA Health Sciences Inc (USNA) Stock
Based on ratings from 1 analysts USANA Health Sciences Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Neutral. The stock has buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on USNA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for USNA is USD 37.00 over the next 12 months. The maximum analyst target price is USD 38 while the minimum anlayst target price is USD 36.
USNA stock's Price/Earning ratio is 13.31.
Our analysis grades USNA stock's Price / Earning ratio at B. This means that USNA stock's Price/Earning ratio is above 17% of the stocks in the Packaged Foods sector in the NYE exchange.
Based on this USNA may be undervalued for its sector.
The last closing price of USNA's stock was USD 24.74.
The most recent market capitalization for USNA is USD 0.55B.
Based on targets from 1 analysts, the average taret price for USNA is projected at USD 37.00 over the next 12 months.
This means that USNA's stock price may go up by +49.56% over the next 12 months.
We can't find any ETFs which contains USANA Health Sciences Inc's stock.
As per our most recent records USANA Health Sciences Inc has 1,700 Employees.
USANA Health Sciences Inc's registered address is 3838 West Parkway Boulevard, Salt Lake City, UT, United States, 84120.
You can get more information about it from USANA Health Sciences Inc's website at https://www.usana.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About USANA Health Sciences Inc (USNA) Stock
Based on ratings from 1 analysts USANA Health Sciences Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Neutral. The stock has buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on USNA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for USNA is USD 37.00 over the next 12 months. The maximum analyst target price is USD 38 while the minimum anlayst target price is USD 36.
USNA stock's Price/Earning ratio is 13.31.
Our analysis grades USNA stock's Price / Earning ratio at B. This means that USNA stock's Price/Earning ratio is above 17% of the stocks in the Packaged Foods sector in the NYE exchange.
Based on this USNA may be undervalued for its sector.
The last closing price of USNA's stock was USD 24.74.
The most recent market capitalization for USNA is USD 0.55B.
Based on targets from 1 analysts, the average taret price for USNA is projected at USD 37.00 over the next 12 months.
This means that USNA's stock price may go up by +49.56% over the next 12 months.
We can't find any ETFs which contains USANA Health Sciences Inc's stock.
As per our most recent records USANA Health Sciences Inc has 1,700 Employees.
USANA Health Sciences Inc's registered address is 3838 West Parkway Boulevard, Salt Lake City, UT, United States, 84120.
You can get more information about it from USANA Health Sciences Inc's website at https://www.usana.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for USNA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
